{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:00:17Z","timestamp":1788210017371,"version":"build-2803163510"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To analyze the efficacy of mycophenolate mofetil (MMF) and glucocorticoid administration in patients with thyroid-associated ophthalmopathy (TAO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Sixty patients with moderate to severe TAO treated in Jingzhou Central Hospital from January 2022 to June 2022 were selected and enrtolled in this study. The subjects were divided into experimental group (n=30) and control group (n=30) based on the random number table method. Glucocorticoid pulse therapy was provided in the control group, while MMF was given in the experimental group on the basis of Control group. Clinical activity score (CAS), quality of life (QOL), visual acuity, eyelid fissure width, intraocular pressure, and degree of exophthalmos were observed at the time of admission and at the 12\n                      <jats:sup>th<\/jats:sup>\n                      week and 24\n                      <jats:sup>th<\/jats:sup>\n                      post-treatment weeks. We compared the immune function (TRAb, IL-6, and CD4+\/CD8+) of the two groups pre-treatment and 24 weeks post-treatment, and evaluated the clinical therapeutic effect.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The clinical effective rates at 12 and 24 weeks in the experimental group were higher (73.3% and 83.3%) than those in the control group (46.7% and 60.0%) (\n                      <jats:italic>P &amp;lt;<\/jats:italic>\n                      0.05). After 12 weeks of treatment, patients\u2019 CAS scores, and bilateral lid fissure width decreased and right eye visual acuity increased in the control group compared with those before treatment (\n                      <jats:italic>P &amp;lt;<\/jats:italic>\n                      0.05); further, after 24 weeks of treatment, patients\u2019 QOL scores and bilateral visual acuity increased and CAS scores, bilateral lid fissure width and proptosis decreased compared with those before treatment, and patients\u2019 QOL scores, CAS scores and bilateral proptosis improved more than those at 12 weeks of treatment (\n                      <jats:italic>P &amp;lt;<\/jats:italic>\n                      0.05). Additionally, greater improvements were observed in the patients\u2019 QOL and CAS scores, and proptosis after 24-week treatment than after 12-week treatment (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.05). In the experimental group, the QOL score and binocular visual acuity increased, whereas the CAS score, intraocular pressure, lid width, and proptosis decreased after 12 weeks of treatment as compared to the values of these parameters in the pre-treatment period (\n                      <jats:italic>P &amp;lt;<\/jats:italic>\n                      0.05); after 24 weeks of treatment, greater improvements were established in the ocular-related indexes improved compared to the pre-treatment period and after 12 weeks of treatment (\n                      <jats:italic>P &amp;lt;<\/jats:italic>\n                      0.05). After 12 weeks of treatment, the patients in the experimental group had more considerable improvements in the right visual acuity, right intraocular pressure, and left lid fissure width than the control group (\n                      <jats:italic>P &amp;lt;<\/jats:italic>\n                      0.05); at 24 weeks of treatment, patients in the experimental group had greater improvements in the QOL score, bilateral visual acuity, intraocular pressure, bilateral lid fissure width, and bilateral proptosis than the control group (\n                      <jats:italic>P &amp;lt;<\/jats:italic>\n                      0.05). No significant differences were found in the values of TRAb, IL-6, and CD4+\/CD8+ between the two groups before treatment (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;gt;0.05); the values of TRAb, IL-6, and CD4+\/CD8+ in the experimental group was significantly lower than those before treatment and in the control group after 24weeks of treatment. (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;gt;0.05). No statistically significant difference was observed in the incidence of liver damage and menstrual disorders between the two groups during the 24 weeks of treatment (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;gt;0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of oral MMF and glucocorticoid shock therapy is an effective drug for the treatment of patients with moderately active TAO.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2023.1140196","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T02:02:40Z","timestamp":1679364160000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients"],"prefix":"10.3389","volume":"14","author":[{"given":"Lan-Fang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Li","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Fan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Fu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology,natural history, risk factors, and prevention of Graves\u2032orbitopathy[J]","volume":"11","author":"Bartalena","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus glucocorticoid versus glucocorticoid alone in active,moderate-to-severe graves\u2019 orbitopathy(MINGO): A randomized,observer-masked,multicentre trial[J]","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn311282-20201208-00813","article-title":"Efficacy and safety of mycophenolate mofetil in the treatment of glucocorticoid-resistant active moderate-to-severe thyroid-associated ophthalmopathy","volume":"37","author":"Ye","year":"2021","journal-title":"Chin J Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112142-20220421-00201","article-title":"Chinese Guidelines for the diagnosis and treatment of thyroid-related eye diseases (2022)","volume":"58","year":"2022","journal-title":"Chin J Ophthalmol"},{"key":"B5","article-title":"Management of graves' eye disease:Interpreting the 2016 European thyroid association and European GO expert group guidelines","volume":"53","author":"Wei","year":"2017","journal-title":"Chin J Ophthalmol"},{"key":"B6","volume-title":"Preliminary clinical investigation on the treatment of thyroid-associated ophthalmopathy with different intravenous regimens of glucocorticoids","author":"Huang","year":"2021"},{"key":"B7","article-title":"Epigenetic regulation and autoimmune disease treatment","volume":"31","author":"Guo","year":"2015","journal-title":"Chin J Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European thyroid association\/ European group on graves' orbitopathy guidelines for the management of graves 'Orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2012.04.012","article-title":"Modulatory effect of mycophenolate mofetil on carrageenan-induced inflammation in the mouse air pouch model","volume":"13","author":"Dalmarco","year":"2012","journal-title":"Int Immunopharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2015.1031444","article-title":"Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephriris in Japan","volume":"25","author":"Yasuda","year":"2015","journal-title":"Mod Rheumatol"},{"key":"B11","article-title":"Exploring the efficacy of partial immunosuppression in graves' ophthalmopathy","volume":"43","author":"Wang","year":"2004","journal-title":"Chin J Internal Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1008-8199.2015.03.011","article-title":"Clinical efficacy of mycophenolate ester in the treatment of active thyroid-associated ophthalmopathy","volume":"28","author":"Hu","year":"2015","journal-title":"J Graduate Med Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.19613\/j.cnki.1671-3141.2020.001.015","article-title":"Meta-analysis and trial sequential analysis of rituximab versus glucocorticoids in the treatment of graves' ophthalmopathy","volume":"20","author":"Zhou","year":"2020","journal-title":"World Abstracts Curr Med Inf (serial electronic journal)"},{"key":"B14","article-title":"An Italian national multicenter study for the definition of reference ranges for normal values of peripheral blood lymphocyte subsets in healthy adults","volume":"84","author":"Santagostino","year":"1999","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.exer.2015.02.007","article-title":"Current perspective on the role of orbital fibroblasts in the pathogenesis of graves 'ophthalmopathy","volume":"142","author":"Dik WA,Virakul","year":"2016","journal-title":"Exp Eye Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1140196\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T02:02:51Z","timestamp":1679364171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1140196\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":15,"alternative-id":["10.3389\/fendo.2023.1140196"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1140196","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"article-number":"1140196"}}